Free-living use of artificial pancreas for children with type 1 diabetes: systematic review

BACKGRAUND: A closed-loop glucose control system or ‘artificial pancreas’ consists of three components – a Continuous Glucose Monitor (CGM), infusion pumps to deliver hormone(s) and a sophisticated dosing algorithm to control hormone delivery. In the past years, numerou...

Full description

Saved in:
Bibliographic Details
Main Authors: Klemen Dovc, Gül Yeşiltepe Mutlu, Yury I. Philippov, Dmitry N. Laptev, Evgenia M. Patrakeeva, Lubov O. Chernilova, Alsu G. Zalevskaya, Marina V. Shestakova, Tadej Battelino
Format: Article
Language:English
Published: Endocrinology Research Centre 2018-08-01
Series:Сахарный диабет
Subjects:
Online Access:https://www.dia-endojournals.ru/jour/article/view/9714
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850254385195515904
author Klemen Dovc
Gül Yeşiltepe Mutlu
Yury I. Philippov
Dmitry N. Laptev
Evgenia M. Patrakeeva
Lubov O. Chernilova
Alsu G. Zalevskaya
Marina V. Shestakova
Tadej Battelino
author_facet Klemen Dovc
Gül Yeşiltepe Mutlu
Yury I. Philippov
Dmitry N. Laptev
Evgenia M. Patrakeeva
Lubov O. Chernilova
Alsu G. Zalevskaya
Marina V. Shestakova
Tadej Battelino
author_sort Klemen Dovc
collection DOAJ
description BACKGRAUND: A closed-loop glucose control system or ‘artificial pancreas’ consists of three components – a Continuous Glucose Monitor (CGM), infusion pumps to deliver hormone(s) and a sophisticated dosing algorithm to control hormone delivery. In the past years, numerous studies with closed-loop system devices were conducted with gradual shift to out-of-hospital environment and with lengthening study duration. AIMS: To compare efficacy and safety of closed-loop insulin pump use in children with type 1 diabetes mellitus in compare with conventional insulin treatment (continuous subcutaneous insulin infusion (CSII) with our without CGM) based on randomized control trials data (RCT). METHODS: In the systematic review we have include 28 randomized controlled trials results indexed in PubMed, Medline databases published till 15 June 2017. The efficacy on metabolic control in this study evaluated by the proportion of time within target range (preferably 70 to 180 mg/dl if reported) and mean (median) glucose based on sensor measurements, and the safety evaluated by time in hypoglycemia (below 70 mg/dl if reported). RESULTS: Increased time in range in the night period was observed in all RCT. Only 3 RCT showed decrease of the time in range within 24 h evaluation period. In one RCT the significant positive differences have been shown in the time in range for dual hormone closed-loop glucose control system in compare with insulin-only artificial pancreas. Mean glycaemia and glucose variability changes were not in the same manner in different RCT, both in the night only and in 24 h estimation period. Night hypoglycemia duration decreased in most RCT with closed-loop control in compare with CSII, and increased only in 2 RCT. When all-day estimation period the time in hypoglycemia changed not in the same manner in different RCT. Valuable methodology differences of the glycaemic control estimation within observed RCT brought significant complications in the data analysis and made impossible the results quantitative estimation to prepare a metaanalysis. CONCLUSIONS: Much work has been done to develop effective and safe artificial pancreas, but not all RCTs confirmed advantages of closed-loop glucose control in compare with CSII in children and adolescents in real life. More research with prospective randomized control design required to prove benefits of closed-loop glucose control. Further RCTs should have an uniform methodology for glycemic control assessment and long duration that will allow to use cumulative measures in a closed-loop efficacy estimation (HbA1c).
format Article
id doaj-art-bb3b843fbf3f4df295dbcc4833fa4fb2
institution OA Journals
issn 2072-0351
2072-0378
language English
publishDate 2018-08-01
publisher Endocrinology Research Centre
record_format Article
series Сахарный диабет
spelling doaj-art-bb3b843fbf3f4df295dbcc4833fa4fb22025-08-20T01:57:08ZengEndocrinology Research CentreСахарный диабет2072-03512072-03782018-08-0121320621610.14341/DM97148524Free-living use of artificial pancreas for children with type 1 diabetes: systematic reviewKlemen Dovc0Gül Yeşiltepe Mutlu1Yury I. Philippov2Dmitry N. Laptev3Evgenia M. Patrakeeva4Lubov O. Chernilova5Alsu G. Zalevskaya6Marina V. Shestakova7Tadej Battelino8<p>UMC-University Children&rsquo;s Hospital</p><p>Ko&ccedil; University Hospital</p><p>Endocrinology Research Centre</p><p>Endocrinology Research Centre</p><p>Pavlov First Saint Petersburg State Medical University</p><p>Pavlov First Saint Petersburg State Medical University</p><p>Pavlov First Saint Petersburg State Medical University</p><p>Endocrinology Research Centre</p><p>UMC-University Children&rsquo;s Hospital, Ljubljana;&nbsp;University of Ljubljana</p>BACKGRAUND: A closed-loop glucose control system or &lsquo;artificial pancreas&rsquo; consists of three components &ndash; a Continuous Glucose Monitor (CGM), infusion pumps to deliver hormone(s) and a sophisticated dosing algorithm to control hormone delivery. In the past years, numerous studies with closed-loop system devices were conducted with gradual shift to out-of-hospital environment and with lengthening study duration. AIMS: To compare efficacy and safety of closed-loop insulin pump use in children with type 1 diabetes mellitus in compare with conventional insulin treatment (continuous subcutaneous insulin infusion (CSII) with our without CGM) based on randomized control trials data (RCT). METHODS: In the systematic review we have include 28 randomized controlled trials results indexed in PubMed, Medline databases published till 15 June 2017. The efficacy on metabolic control in this study evaluated by the proportion of time within target range (preferably 70 to 180 mg/dl if reported) and mean (median) glucose based on sensor measurements, and the safety evaluated by time in hypoglycemia (below 70 mg/dl if reported). RESULTS: Increased time in range in the night period was observed in all RCT. Only 3 RCT showed decrease of the time in range within 24 h evaluation period. In one RCT the significant positive differences have been shown in the time in range for dual hormone closed-loop glucose control system in compare with insulin-only artificial pancreas. Mean glycaemia and glucose variability changes were not in the same manner in different RCT, both in the night only and in 24 h estimation period. Night hypoglycemia duration decreased in most RCT with closed-loop control in compare with CSII, and increased only in 2 RCT. When all-day estimation period the time in hypoglycemia changed not in the same manner in different RCT. Valuable methodology differences of the glycaemic control estimation within observed RCT brought significant complications in the data analysis and made impossible the results quantitative estimation to prepare a metaanalysis. CONCLUSIONS: Much work has been done to develop effective and safe artificial pancreas, but not all RCTs confirmed advantages of closed-loop glucose control in compare with CSII in children and adolescents in real life. More research with prospective randomized control design required to prove benefits of closed-loop glucose control. Further RCTs should have an uniform methodology for glycemic control assessment and long duration that will allow to use cumulative measures in a closed-loop efficacy estimation (HbA1c).https://www.dia-endojournals.ru/jour/article/view/9714diabetes mellitus, type 1insulin infusion systemspancreas, artificialclosed-loopcsiicgmsensor augmented pumpsystematic reviewrandomized control trialchildren
spellingShingle Klemen Dovc
Gül Yeşiltepe Mutlu
Yury I. Philippov
Dmitry N. Laptev
Evgenia M. Patrakeeva
Lubov O. Chernilova
Alsu G. Zalevskaya
Marina V. Shestakova
Tadej Battelino
Free-living use of artificial pancreas for children with type 1 diabetes: systematic review
Сахарный диабет
diabetes mellitus, type 1
insulin infusion systems
pancreas, artificial
closed-loop
csii
cgm
sensor augmented pump
systematic review
randomized control trial
children
title Free-living use of artificial pancreas for children with type 1 diabetes: systematic review
title_full Free-living use of artificial pancreas for children with type 1 diabetes: systematic review
title_fullStr Free-living use of artificial pancreas for children with type 1 diabetes: systematic review
title_full_unstemmed Free-living use of artificial pancreas for children with type 1 diabetes: systematic review
title_short Free-living use of artificial pancreas for children with type 1 diabetes: systematic review
title_sort free living use of artificial pancreas for children with type 1 diabetes systematic review
topic diabetes mellitus, type 1
insulin infusion systems
pancreas, artificial
closed-loop
csii
cgm
sensor augmented pump
systematic review
randomized control trial
children
url https://www.dia-endojournals.ru/jour/article/view/9714
work_keys_str_mv AT klemendovc freelivinguseofartificialpancreasforchildrenwithtype1diabetessystematicreview
AT gulyesiltepemutlu freelivinguseofartificialpancreasforchildrenwithtype1diabetessystematicreview
AT yuryiphilippov freelivinguseofartificialpancreasforchildrenwithtype1diabetessystematicreview
AT dmitrynlaptev freelivinguseofartificialpancreasforchildrenwithtype1diabetessystematicreview
AT evgeniampatrakeeva freelivinguseofartificialpancreasforchildrenwithtype1diabetessystematicreview
AT lubovochernilova freelivinguseofartificialpancreasforchildrenwithtype1diabetessystematicreview
AT alsugzalevskaya freelivinguseofartificialpancreasforchildrenwithtype1diabetessystematicreview
AT marinavshestakova freelivinguseofartificialpancreasforchildrenwithtype1diabetessystematicreview
AT tadejbattelino freelivinguseofartificialpancreasforchildrenwithtype1diabetessystematicreview